Healthcare technology serving behavioral health.

Diligence on the companies selling into behavioral health — EHR, revenue cycle, measurement-based care, and virtual delivery — judged against how the practices on the other end actually run.

Overview

This is the sector view of healthcare technology: the companies as investment targets, rather than the systems inside a provider deal. The practice area covers the second — what an acquired platform runs on, and what consolidating it costs. This page covers the first.

Behavioral health software is sold to buyers who are usually clinician-owners and always short on administrative capacity, and it is used by clinicians who will route around anything that adds minutes per encounter. That produces a specific pattern: contracted seats that do not convert into active use, revenue reported per provider while the provider count includes clinicians who logged in twice, and churn that surfaces at renewal rather than in the cohort data. Percent-of-collections pricing in revenue cycle products moves the risk again, tying revenue to a customer’s payer mix and denial performance.

We read those businesses from the customer’s side, against the billing, workflow, and operating behavior of the practices they serve.

What We Assess

Revenue model and quality. Per-provider, per-seat, or percent-of-collections pricing, contracted versus active users, implementation and services revenue separated from recurring, and the concentration of revenue in the largest accounts.
Clinician adoption. Active use by role, the workflow minutes the product adds or removes per encounter, and whether adoption survives the end of onboarding support.
Churn and retention. Gross and net retention by cohort and by segment, the churn concentrated in small practices, and the difference between a logo renewing and a customer using the product.
Implementation reality. Time to go live against what was sold, data migration history, the services headcount required per implementation, and the backlog carried as revenue.
Clinical and outcome claims. Whether measurement-based care and outcome claims are supported by the data the product collects, and whether customers can use them with a payer.
Regulatory exposure. HIPAA posture and business associate agreements, 42 CFR Part 2 handling for substance use records, telehealth prescribing and state licensure dependencies, and the concentration of risk in a single regulatory assumption.

Edisa serves as an executive at a healthcare technology company. Engagements involving competing or adjacent vendors are disclosed in advance and declined where a conflict exists.

Who This Is For

Investors evaluating a software, revenue cycle, or virtual care company selling into behavioral health.
Sponsors testing a technology target’s reported adoption and retention against provider operating behavior.
Technology companies preparing for diligence and expecting their clinical workflow claims to be examined.

Practice Area